Search Results

AOP Orphan Pharmaceuticals GmbH continues a successful clinical research program in hematology/oncology with two abstracts accepted for presentation at the European Hematology Association 2024 hybrid congress in Madrid, Spain.

AOP Orphan Pharmaceuticals GmbH announced the publication of final results on the recently developed interferon therapy, ropeginterferon alfa-2b, in patients with polycythemia vera in the prestigious journal Leukemia.

AOP Orphan Pharmaceuticals GmbH announced the results of an analysis assessing the impact of an individually optimized dosing regimen of ropeginterferon alfa-2b on treatment response in patients with low-risk polycythaemia vera 1 These new data show that some low-risk PV patients require and can tolerate high ropeginterferon alfa-2b doses, and that the optimal dose varies substantially between patients.

Rocket Pharmaceuticals, Inc. today announced that the European Commission (EC), based on a positive opinion issued by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA), has granted orphan medicinal product designation for RP-A601.

60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharmaceuticals”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that the U.S. Food and Drug Administration (“FDA”) has granted its investigational tafenoquine candidate orphan drug designation for the treatment of patients with acute babesiosis.

Agomab Therapeutics NV announced that it has received Orphan Drug Designation from the U.S. Food and Drug Administration for AGMB-447, its inhaled, small molecule inhibitor of ALK5.